Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
PT Industri Jamu dan Farmasi Sido Muncul Tbk
Sido Muncul makes and sells herbal medicines, supplements, and health drinks to consumers across Indonesia.
Sido Muncul is Indonesia's best-known maker of jamu — the country's traditional herbal medicine — sold as pills, powders, capsules, and bottled tonics that people take for everyday aches, low energy, and general health. Its most famous product is Tolak Angin, a minty herbal liquid for feeling under the weather, which is close to a household name in Indonesia. The company also sells energy and health drinks, including Kuku Bima, plus supplements, food products, and a smaller line of pharmaceuticals, and it runs its own factories and packaging so it controls most of the production from raw herbs to finished bottle.
The business runs on two money engines. The bigger one is putting its herbal products onto shop shelves and into pharmacies, supermarkets, and small neighborhood stores across the country, sold mostly under its own brand. The second is contract manufacturing: Sido Muncul's factories also make products for other companies that want its production know-how without building their own plants. Selling its own brands gives it the name recognition and repeat buyers; the contract work fills spare factory capacity and adds volume. Its edge comes from something hard to copy: decades of trust. Tolak Angin has been around since the 1930s and was one of the first jamu products packaged and sold nationally, which means many Indonesians grew up with it in the house. That brand loyalty lets Sido Muncul charge more than generic herbal sellers and keep customers coming back. It also helps that the company grows and processes much of its own raw material, giving it more control over quality and cost than rivals that buy finished goods and slap on a label.
The company is a steady cash generator, and it has a habit of handing much of that cash back to shareholders as dividends rather than hoarding it. That makes it a favorite of income-focused investors on the Jakarta exchange. The main risks are familiar ones: it depends heavily on the Indonesian consumer, competition from cheaper generics and imported supplements is real, and fads in health products can shift demand. But a brand that has survived nearly a century of Indonesian history is a durable thing, and that longevity is the core of the investment case.
Saved answer · last researched 12 Nov 2026